Related Experiment Video

Updated: Jun 11, 2025

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.0K

Tumor NOS2 and COX2 Spatial Juxtaposition with CD8+ T Cells Promote Metastatic and Cancer Stem Cell Niches that Lead

Lisa A Ridnour1, William F Heinz2, Robert Y S Cheng1

  • 1Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland.

Cancer Research Communications
|October 2, 2024
PubMed
Abstract

Insights

This study reveals distinct CD8+ T cell neighborhoods that predict patient outcomes in tumors. These areas can be targeted using existing nitric oxide synthase (NOS) inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs).

Area of Science:

  • Immunology
  • Oncology
  • Spatial Biology

Background:

  • Tumor microenvironments are complex, with spatial arrangements of immune cells influencing clinical outcomes.
  • Understanding the specific cellular neighborhoods within tumors is crucial for developing effective cancer therapies.

Purpose of the Study:

  • To identify unique cellular neighborhoods associated with CD8+ T cell infiltration in tumors.
  • To determine if these neighborhoods predict clinical outcomes.
  • To explore potential therapeutic targets within these identified cellular neighborhoods.

Main Methods:

  • Spatial transcriptomics and multiplex immunofluorescence were used to analyze tumor immune architecture.
  • Identification of specific cell populations and their spatial relationships.

Main Results:

  • Discovery of two distinct CD8+ T cell neighborhoods: CD8-NOS2+COX2+ and CD8-NOS2-COX2+.
  • These cellular neighborhoods were found to be predictive of clinical outcomes in cancer patients.
  • The identified pathways involve nitric oxide synthase (NOS2) and cyclooxygenase-2 (COX2).

Conclusions:

  • Specific CD8+ T cell spatial architectures, defined by NOS2 and COX2 expression, are critical drivers of tumor immunity and clinical prognosis.
  • Clinically available nitric oxide synthase (NOS) inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs) represent potential therapeutic strategies targeting these neighborhoods.

More Related Videos

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors07:01

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors

Published on: March 1, 2020

10.1K
A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer07:35

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

Published on: December 26, 2016

40.9K

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.8K